Data / Drug companies / Carwin Pharmaceutical Associates, LLC
Carwin Pharmaceutical Associates, LLC: 17 products in the FDA NDC directory, labeler code 15370
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Carwin Pharmaceutical Associates, LLC (labeler code 15370) lists 17 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 17 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on February 19, 2026.
The request: Watch Carwin Pharmaceutical Associates, LLC (FDA labeler code 15370): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 15370
- Products in commercial distribution
- 17
- Packages
- 33
- Finished drugs by generic name
- 8
- Prescription products
- 17
- Over the counter products
- 0
- Flagged as original packager
- 17 of 17 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- January 6, 2014
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 8 | 47.1% |
| Generic drugs (ANDA) | 5 | 29.4% |
| Other unapproved drugs | 4 | 23.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 17 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Potassium chloride | 3 | 84 |
| Aripiprazole | 3 | 49 |
| Diclofenac potassium | 2 | 42 |
| Nabumetone | 1 | 30 |
| Carbinoxamine maleate | 1 | 9 |
| Dexchlorpheniramine maleate | 1 | 2 |
| Clotrimazole | 1 | 98 |
| Celecoxib | 1 | 63 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Liquid | 3 | 17.6% |
| Tablet, chewable | 3 | 17.6% |
| Film, soluble | 3 | 17.6% |
| Tablet | 2 | 11.8% |
| Tablet, film coated | 2 | 11.8% |
| Powder, for solution | 2 | 11.8% |
| Capsule, liquid filled | 1 | 5.9% |
| Suspension | 1 | 5.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| CLOTIC (clotrimazole) otic solution | 15370-220 | Liquid | New drug applications (NDA) | February 19, 2026 |
| POKONZA potassium chloride | 15370-307 | Liquid | New drug applications (NDA) | January 14, 2026 |
| Pokonza | 15370-306 | Powder, for solution | New drug applications (NDA) | December 9, 2025 |
| Vyscoxa | 15370-501 | Suspension | New drug applications (NDA) | July 31, 2025 |
| Opipza | 15370-403 | Film, soluble | New drug applications (NDA) | November 1, 2024 |
| Opipza | 15370-402 | Film, soluble | New drug applications (NDA) | November 1, 2024 |
| Opipza | 15370-401 | Film, soluble | New drug applications (NDA) | November 1, 2024 |
| Diclofenac Potassium | 15370-185 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2023 |
| Pokonza | 15370-305 | Powder, for solution | New drug applications (NDA) | September 19, 2023 |
| Lofena | 15370-180 | Tablet, film coated | Generic drugs (ANDA) | October 25, 2021 |
| Relafen ds | 15370-170 | Tablet | Generic drugs (ANDA) | September 20, 2019 |
| Ryclora | 15370-150 | Liquid | Generic drugs (ANDA) | October 7, 2018 |
| RyVent | 15370-130 | Tablet | Generic drugs (ANDA) | February 17, 2017 |
| TriStart DHA | 15370-250 | Capsule, liquid filled | Other unapproved drugs | June 1, 2015 |
| Quflora Pediatric | 15370-105 | Tablet, chewable | Other unapproved drugs | January 6, 2014 |
| Quflora Pediatric | 15370-104 | Tablet, chewable | Other unapproved drugs | January 6, 2014 |
| Quflora Pediatric | 15370-103 | Tablet, chewable | Other unapproved drugs | January 6, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.